AlloRx

Phase 1Cell therapy

TThe Foundation for Orthopaedics and Regenerative Medicine

AlloRx is one of 231 biologic programs targeting Cerebral Palsy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

230

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyRecruiting

Polycystic Ovary SyndromeRecruiting

Rheumatoid ArthritisRecruiting

LupusRecruiting

Multiple SclerosisRecruiting

OsteoarthritisRecruiting

Eye DiseasesRecruiting

Inflammatory Bowel DiseasesRecruiting

Traumatic Brain InjuryNot yet recruiting

Pulmonary DiseaseRecruiting

Cerebral PalsyPhase 1

Recruiting

Polycystic Ovary SyndromePhase 1

Recruiting

Rheumatoid ArthritisPhase 1

Recruiting

LupusPhase 1

Recruiting

Multiple SclerosisPhase 1

Recruiting

OsteoarthritisPhase 1

Recruiting

Eye DiseasesPhase 1

Recruiting

Inflammatory Bowel DiseasesPhase 1

Recruiting

Traumatic Brain InjuryPhase 1

Not yet recruiting

Pulmonary DiseasePhase 1

Recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

176 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

AlloRx

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 3

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Nsaids

Roche

Preclinical

1 9

Disalcid

JJoslin Diabetes Center

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Cerebral Palsy

NCT05018819

Phase 1Recruiting

Polycystic Ovary Syndrome

NCT06143527

Phase 1Recruiting

Autism

NCT05003960

Phase 1Recruiting

Frailty

NCT05018767

Phase 1Recruiting

Osteoarthritis

NCT05147675

Q1 2028

Phase 1Recruiting

Spinal Cord Injuries

NCT05152290

Clinical

Trials by Indication[1]

20 more indications

Autism1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003960·15 enrolled

Systemic Sclerosis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05016804·20 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05016817·20 enrolled

Frailty1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018767·86 enrolled

Lupus1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018858·15 enrolled

Diabetes1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Diabetes

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003908·2 enrolled

Congestive Heart Failure1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Heart Disease

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147766·3 enrolled

Erectile Dysfunction1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147779·20 enrolled

Chronic Kidney Diseases1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Chronic Kidney Disease.

Terminated·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018845·20 enrolled

Rheumatoid Arthritis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for the Treatment of Rheumatoid Arthritis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003934·20 enrolled

Inflammatory Bowel Diseases1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Crohn's Disease or Ulcerative Colitis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003947·15 enrolled

Skin ulcer1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Skin Ulcer

Not yet recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158127·20 enrolled

Multiple Sclerosis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003388·15 enrolled

Cerebral Palsy1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018819·15 enrolled

Osteoarthritis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147675·92 enrolled

Eye Diseases1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for the Treatment of Non-arteritic Ischemic Optic Neuropathy

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147701·20 enrolled

Pulmonary Disease1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Pulmonary Diseases

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147688·20 enrolled

Traumatic Brain Injury1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury

Not yet recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05018832·20 enrolled

Tourette syndrome1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Tourette Syndrome

Withdrawn·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158439

Amyotrophic Lateral Sclerosis1 trial

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis

Withdrawn·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05003921

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for AlloRx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AlloRx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AlloRx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Foundation for Orthopaedics and Regenerative Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TThe Foundation for Orthopaedics and Regenerative Medicine

AlloRx

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Spinal Cord Injuries2 trials

Osteoporosis1 trial

Injury1 trial

Mesenchymal Stem Cells1 trial

Polycystic Ovary Syndrome1 trial

Autism1 trial

Systemic Sclerosis1 trial

Idiopathic Pulmonary Fibrosis1 trial

Frailty1 trial

Lupus1 trial

Diabetes1 trial

Congestive Heart Failure1 trial

Erectile Dysfunction1 trial

Chronic Kidney Diseases1 trial

Rheumatoid Arthritis1 trial

Inflammatory Bowel Diseases1 trial

Skin ulcer1 trial

Multiple Sclerosis1 trial

Cerebral Palsy1 trial

Osteoarthritis1 trial

Eye Diseases1 trial

Pulmonary Disease1 trial

Traumatic Brain Injury1 trial

Tourette syndrome1 trial

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News